Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -35.27% is 23% above its 5-year average of -46.02%, near the high end of its 5-year range (-84.35%–-29.85%).
5.25% above its 12-month average of -37.23%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.59%.
RETURN ON ASSETS (ROA)
-35.27%
RETURN ON ASSETS (ROA) AVG TTM
-37.23%
RETURN ON ASSETS (ROA) AVG 3Y
-38.20%
RETURN ON ASSETS (ROA) AVG 5Y
-46.02%
RETURN ON ASSETS (ROA) AVG 10Y
-81.80%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.25%
CURRENT VS 3Y AVG
+7.66%
CURRENT VS 5Y AVG
+23.36%
CURRENT VS 10Y AVG
+56.88%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-9.40%
vs the sector median at left
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Return on Assets (ROA)
-35.27%
TTM Avg
-37.23%
3Y Avg
-38.20%
5Y Avg
-46.02%
Market Cap
$2.06B
Return on Assets (ROA)
-38.42%
TTM Avg
-32.16%
3Y Avg
-31.63%
5Y Avg
-27.96%
Market Cap
$2.08B
Return on Assets (ROA)
-11.31%
TTM Avg
-8.55%
3Y Avg
-34.29%
5Y Avg
-31.66%
Market Cap
$2.05B
Return on Assets (ROA)
4.82%
TTM Avg
2.89%
3Y Avg
-0.31%
5Y Avg
-0.49%
Market Cap
$2.03B
Return on Assets (ROA)
10.98%
TTM Avg
8.41%
3Y Avg
7.65%
5Y Avg
11.22%
Market Cap
$2.02B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$2.11B
Return on Assets (ROA)
-22.33%
TTM Avg
-96.60%
3Y Avg
-247.71%
5Y Avg
-184.26%
Market Cap
$2.02B
Return on Assets (ROA)
-38.65%
TTM Avg
-60.49%
3Y Avg
-64.82%
5Y Avg
-76.19%
Market Cap
$2.02B
Return on Assets (ROA)
39.65%
TTM Avg
19.63%
3Y Avg
0.51%
5Y Avg
-8.90%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | -35.27% | -37.23% | -38.20% | -46.02% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -38.42% | -32.16% | -31.63% | -27.96% |
| Alvotech (ALVO)vs › | $2.08B | -11.31% | -8.55% | -34.29% | -31.66% |
| Vericel Corporation (VCEL)vs › | $2.05B | 4.82% | 2.89% | -0.31% | -0.49% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 10.98% | 8.41% | 7.65% | 11.22% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | -68.96% | 16.60% | -13.89% | -23.58% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -22.33% | -96.60% | -247.71% | -184.26% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | -38.65% | -60.49% | -64.82% | -76.19% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 39.65% | 19.63% | 0.51% | -8.90% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | -75.40% | -31.99% | -46.60% | -53.88% |
ROA
-35.3%
ROE
-58.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -38.09% |
| 2024-12-31 | -36.36% |
| 2023-12-31 | -48.48% |
| 2022-12-31 | -29.85% |
| 2021-12-31 | -38.98% |
| 2020-12-31 | -84.35% |
| 2019-12-31 | -138.37% |
| 2018-12-31 | -49.44% |
| 2017-12-31 | -50.52% |
| 2016-12-31 | -297.58% |
| 2015-12-31 | -87.80% |
| 2014-12-31 | -97.54% |
| 2013-12-31 | -58.80% |
| 2012-12-31 | -259.34% |
